Publications
5677 Results
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 17; abstr LBA4500), abst. LBA4500; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S0931
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study (SWOG S0931, NCT01120249)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 8054), poster 477; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Myeloma
- Study Number(s)
- S1211
Follow-Up Analysis of the Randomized Phase II Trial of Bortezomib, Lenalidomide, Dexamthasone with/without Elotuzumab for Newly Diagnosed, High Risk Multiple Myeloma (SWOG-1211)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 5071), poster 254; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from SWOG S1216, a phase III trial of ADT with or without orteronel
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 4581), poster 72; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1314
S1314 Correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9046), poster 34; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for Previously Treated Stage IV or recurrent Squamous Cell Lung Cancer patients from the Phase III SWOG LungMAP S1400I trial
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9044), poster 32; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1400I
Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9502), abstract 9502; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1512
Neoadjuvant PD-1 Blockade in Patients with Resectable Desmoplastic Melanoma (SWOG 1512)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 12024), poster 270; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Symptom Management and Survivorship
- Study Number(s)
- S1714
Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9060), poster 48; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1900C
A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic Stk11 Genomic Alterations (SWOG S1900C, LUNG-MAP SUB-STUDY, NCT#04173507)
- Journal / Conference
- J Clin Oncol 40, 2022 (suppl 16; abstr 9004), Abstract #9004; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL), oral
- Year
- 2022
- Research Committee(s)
- Lung
- Study Number(s)
- S1800A